When was Manus Bio founded?

Manus Bio was founded in 2011 and raised its 1st funding round 1 year after it was founded.

Where is Manus Bio located?

Manus Bio is headquartered in Cambridge, United States.

How many employees does Manus Bio have?

As of May 31, 2026, the latest employee count at Manus Bio is 176.

Is Manus Bio a funded company?

Manus Bio is a funded company, having raised a total of $125M across 19 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jan 01, 2012.

When was the latest funding round of Manus Bio?

Manus Bio's latest funding was a $***** Series B round on May 31, 2023, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.17B in funding in 2026 to date.

Where does Manus Bio rank among its competitors?

Manus Bio ranks 5th amongst 61 active competitors, of which 24 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was mbiomics, which secured $14.1M in Apr, 2026.

Who are the top competitors of Manus Bio?

Manus Bio's top competitors include Biotia, Kallyope and mbiomics. Among them, mbiomics secured the most recent funding round in April, 2026.

Manus Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of phytochemicals using microbial fermentation. It produces sustainable eco-friendly products using natural resources for our daily life needs. They recreate natural processes in the microorganism. It converts carbon and plant-derived substrates to produce natural ingredients, with applications as flavours, fragrance, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals.

Website: www.manusbio.com/
Social
Email ID: *****@manusbio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2011

Location

Cambridge, United States

Stage

Series B

Total Funding

$125M in 19 rounds

Latest Funding Round

Series B, May 31, 2023, $*****

Investors

Nelstone Ventures & 18 more

Ranked

5^th among 61 active competitors

Employee Count

176 as on May 31, 2026

Similar Companies

Biotia & 69 more

View Manus Bio's full profile

Manus Bio has raised a total funding of $125M over 19 rounds. Its first funding round was on Jan 01, 2012. Manus Bio has 19 institutional investors.

Here is the list of recent funding rounds of Manus Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 31, 2023	9236079	Series B	7341305	7464089	2463290	1816660
Sep 01, 2022	6613483	Grant (prize money)	2989926	7073118	3199000	Gates
Nov 06, 2020	8444531	Series B	3892988	4753308	BBGI	8570809

Access funding benchmarks and valuations. Sign up today!

View details of Manus Bio's funding rounds and investors

The founders of Manus Bio are Christopher Pirie and Gregory Stephanopoulos. Ajikumar Parayil is the CEO of Manus Bio.

Here are the details of Manus Bio's key team members:

Christopher Pirie: Former Co-Founder of Manus Bio and founder of 2 other companies, Virvio and Virvio.
Gregory Stephanopoulos: Co-Founder of Manus Bio.
Contact Info: 1 email address

View details of Manus Bio's Founder profiles and Board Members

Manus Bio's employee count trend

Manus Bio has 176 employees as of May 26. Here is Manus Bio's employee count trend over the years:

Uncover Manus Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Manus Bio include Biotia, Kallyope and mbiomics. Here is the list of Top 10 competitors of Manus Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biotia 2016, Brooklyn (United States), Series A	Provider of sequencing-based solutions for hospitals	$10.4M	OCA Ventures, Leawood Venture Capital & 16 others	59/100
2nd	Kallyope 2014, New York City (United States), Series D	Discovering novel therapeutics for neurological and metabolic diseases	$479M	The Column Group, Illumina Ventures & 21 others	59/100
3rd	mbiomics 2020, Munich (Germany), Series A	Provider of a genomic-based platform for microbiome-based therapeutics development	$35.2M	MIG Fonds, Bayern Kapital & 1 others	55/100
4th	BioCorteX 2021, London (United Kingdom), Seed	Developer of human-microbiome platform for drug development	$5M	Sofinnova Partners, Hoxton Ventures & 1 others	53/100
5th	Manus Bio 2011, Cambridge (United States), Series B	Developer of phytochemicals using microbial fermentation	$125M	Nelstone Ventures, Gates & 17 others	52/100
6th	Zymochem 2014, Berkeley (United States), Series A	Provider of engineered microbes and biosynthetic pathways for industrial chemicals	$25.4M	Breakout Ventures, Cavallo Ventures & 13 others	49/100
7th	Arborea 2015, London (United Kingdom), Series A	Developer of technology producing protein and ingredients using carbon dioxide	$9.49M	BGF, Plug and Play Tech Center & 14 others	47/100
8th	Kaleido Biosciences 2015, Cambridge (United States), Deadpooled	Developer of microbiome metabolic therapies for inflammatory conditions	$165M	Fidelity Investments, Invus & 7 others	44/100
9th	MicroByre 2017, San Francisco (United States), Seed	Developer of genetically engineered strains of microorganisms	$7.67M	Planetary Technologies, Climate Capital & 6 others	44/100
10th	MicroGen Diagnostics 2011, Orlando (United States), Seed	Provider of sequencing and molecular diagnostic services	$1.65M	-	43/100